Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Heparin Dose and Post Operative Bleeding in Cardiopulmonary Bypass Patients

3. juli 2014 oppdatert av: Mark Rosin, University of Saskatchewan

Blood is anticoagulated using a drug named heparin during open-heart surgery to allow it to safely pass through the heart-lung machine which pumps the blood throughout the body during the surgery. Each patient is given the heparin they need for their surgery. This means some patients receive more or less heparin than other patients. In this study, the investigators will be evaluating the current anticoagulation protocol for open heart surgery in use at the Royal University Hospital. The goal of this project is to compare patients who require and receive more heparin for proper anticoagulation to those patients who require and receive less heparin.

Open-heart surgery will proceed according to the standard hospital protocol. All research participants will be treated according to standard post-open heart surgery protocol in the ICU. This will include measurement of blood loss by keeping track of chest tube outputs and administration of blood transfusions.

This study focuses on Saskatoon Health Region patients having open heart surgery in terms of the protocol for anticoagulation and blood transfusions.

Studieoversikt

Status

Fullført

Forhold

Detaljert beskrivelse

This study examines heparin doses of patients having cardiopulmonary bypass supported surgery in terms of their sensitivity and resistance to heparin which is the standard anticoagulant used. The investigators use the Heparin Management System, an analyser that performs a heparin dose response test. In this test, a patient's whole blood is mixed with increasing amounts of heparin to determine the required dose to achieve a set level of anticoagulation. Patients who are found to resistant to heparin and needing a higher dose are thought by some to bleed more post operatively. It is my view that when the patient is given the correct amount of heparin which is then reversed by the correct amount of protamine (the reversal agent) the bleeding is not determined by heparin dose.

Hypothesis statement: Higher doses of heparin do not cause increased postoperative bleeding and transfusion events in the postoperative CPB patient.

Purposes of the Study

  1. Compare heparin sensitive and resistant patients in terms of postoperative bleeding and transfusion events.
  2. Determine the incidence of heparin sensitivity or resistance in patients.
  3. Identify preoperative factors that lead to heparin resistance or sensitivity in patients.
  4. Using the Heparin Dose Response test in determining heparin resistant and sensitive patients.
  5. Examination of anticoagulation protocol for open-heart surgery.
  6. Effect of preoperative antiplatelet and anticoagulant therapy on perioperative care.
  7. Use routine laboratory tests and values as well as common clinically available values in the conduct of the study so that results would be clinically relevant.

This is a prospective observational study. Patients will be divided into two groups dependant upon the results of their heparin dose response test; sensitive or resistant. Two groups of thirty will be selected to achieve 90% power at the 0.025 level of significance using a one-sided two-sample t-test.

The primary investigator will collect all data and submit the means to the statistician. Based on anecdotal experience the investigators expect there will be no difference between the two groups in terms of chest tube losses and transfusion events post-operatively.

This work is quite relevant to the investigators daily practice. Every open heart patient is anticoagulated with heparin and bleeds post operatively. The investigators goal is a reproducibly safe anticoagulation level and an acceptable level of chest tube losses. This translates to getting patients out of the operating room in a timely fashion and minimizing transfusion events.

Studietype

Observasjonsmessig

Registrering (Faktiske)

66

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

  • Canada
    • Saskatchewan
      • Saskatoon, Saskatchewan, Canada, S7N 0W8
        • Royal University Hospital
      • Saskatoon, Saskatchewan, Canada, S7S 1E1
        • Royal University Hospital

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

40 år til 85 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

On the date of surgery, the patient would be brought to the operating room. The first blood sample would be drawn prior to heparinization. This would include analysis for Activated Clotting Time, Heparin Concentration/Heparin Dose Response, antithrombin and Thrombelastograph. During this first sampling interval, the patient's Heparin Sensitivity or Resistance is determined by Heparin Dose Response (slope). The following values would determine which one of the two study groups the patient would be assigned:

  • Sensitive to heparin: at or above 90 seconds/unit/millilitre
  • Resistant to heparin: below 89 seconds/unit/millilitre

Beskrivelse

Inclusion Criteria:

  • Patients scheduled for elective or urgent CABG of two to six vessels.

Exclusion Criteria:

  • Preoperative:
  • Hemoglobin of less than 110grams/Litre
  • Under 18 years of age
  • Mass less than 75 kilograms
  • Presence of an intra-aortic balloon pump
  • Emergency surgery, requiring operative intervention within 24 hours of consultation to the cardiac surgery team
  • Need for cardiac surgical intervention in addition to planned CABG (with the exception of patent foramen ovale closure)
  • Ejection fraction of less than 50%, as determined by echocardiogram or angiography
  • Pulmonary hypertension with pulmonary artery pressures greater than 60mmHg
  • Presence of infectious endocarditis
  • Hepatic failure with impaired liver function, including INR greater than 1.5 Known diagnosed bleeding disorder
  • History of heparin induced thrombocytopenia and thrombosis
  • Renal failure with pre-operative creatinine greater than 200ml/min or oliguria with urine output less than 10millilitres/hour
  • Allergy to tranexamic acid
  • Pregnancy

Intraoperative:

  • Discovery of infectious endocarditis
  • Need for cardiac surgical intervention in addition to planned coronary CABG

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: Kohort
  • Tidsperspektiver: Potensielle

Kohorter og intervensjoner

Gruppe / Kohort
Heparin Resistant
Patient whose slope calculated by a heparin dose response test is 89 sec/iu/ml or less.
Heparin Sensitive
Patient whose slope calculated by a heparin dose response test is 90 sec/iu/ml or more.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Chest Tube Losses
Tidsramme: Chest tube losses are recorded from departure from operating room to chest tube removal in the ICU (normally less than 24 hrs)
Chest tube losses will be measured in millilitres upon arrival in the Intensive Care unit (ICU) after six hours in the ICU and total chest tube losses during the ICU stay. Chest tube losses are the amount of blood collected in a graduated chest tube collection reservoir from chest tubes placed in the patient's chest wound at the end of surgery.
Chest tube losses are recorded from departure from operating room to chest tube removal in the ICU (normally less than 24 hrs)

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Transfusion Events
Tidsramme: Data collection begins with patient arrival in the operating room and ends with discharge from the ICU (normally less than 24hrs)
Transfusion events to recorded will be the number of patients receiving units of red blood cells, units of platelets, units of plasma and units of cryoprecipitate.
Data collection begins with patient arrival in the operating room and ends with discharge from the ICU (normally less than 24hrs)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

University of Saskatchewan

Etterforskere

  • Hovedetterforsker: Mark W Rosin, MPS, Saskatoon Health Region

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart

1. mai 2012

Primær fullføring (Faktiske)

1. januar 2013

Studiet fullført (Faktiske)

1. januar 2013

Datoer for studieregistrering

Først innsendt

6. mars 2012

Først innsendt som oppfylte QC-kriteriene

5. april 2012

Først lagt ut (Anslag)

10. april 2012

Oppdateringer av studieposter

Sist oppdatering lagt ut (Anslag)

8. juli 2014

Siste oppdatering sendt inn som oppfylte QC-kriteriene

3. juli 2014

Sist bekreftet

1. juli 2014

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • 12-37

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Kliniske studier på Koronararteriesykdom

Søk i lignende forsøk

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

CROs by country

CROs in Belarus

Forhold

Sjeldne sykdommer

Legemiddelintervensjoner

Kosttilskudd

Sponsor / samarbeidspartnere

Steder

3
Abonnere